PIÙ MEDICAL: THE BOARD OF DIRECTORS APPROVES THE CONSOLIDATED HALF-YEARLY FINANCIAL REPORT AS OF JUNE 30, 2026

Pro forma revenue up 31%. Integration of acquired pharmacies continues, as does the strengthening of the platform to support growth

- **Pro forma consolidated revenue of €17.5 million, up 31% from €13.4 million as of June 30, 2025 pro forma;**
- **Pro forma adjusted EBITDA from Pharmacies of €2.5 million, up 16% from €2.2 million as of June 30, 2025 pro forma;**
- **Pro forma adjusted consolidated EBITDA of €1.8 million, compared to €2.0 million as of June 30, 2025 pro forma, with an EBITDA margin of 10.4%, compared with 14.8% in 1H 2025;**
- **Pro forma consolidated net income of €0.6 million (€0.1 million as of June 30, 2025, on a pro forma basis);**
- **Consolidated net financial position (*cash positive*) of €3.1 million (€8.8 million before IFRS 16), compared with a *cash-positive* position of €4.9 million as of December 31, 2025 (€11.4 million before IFRS 16).**

Castronno (VA), 30 September 2026 – The Board of Directors of **Più Medical S.p.A.** ("**Più Medical**", the "**Company**"), a company whose shares are traded on Euronext Growth Milan and which is active in the development and management of pharmacies and integrated healthcare services, met today and approved the consolidated half-yearly financial report as of June 30, 2026, including the Company's pro forma consolidated financial statements.

Stefano Maroni, CEO of Più Medical, said: *"The first half of 2026 represents an important phase for Più Medical in the process of building the industrial platform we have outlined to the market. Pro forma consolidated revenue grew by 31%, and pro forma adjusted EBITDA from pharmacies increased by 16%, despite the fact that the half-year was marked by significant investments in the integration and refurbishment of acquired pharmacies, the recruitment of new professional talent, and the strengthening of the Group's central structure.*
As we have indicated from the outset, the integration of a newly acquired pharmacy is an industrial process that takes approximately 12 months to fully realize its potential. We are investing in our stores, our people, and the expansion of our product offering with the goal of progressively developing their growth and profitability potential.
At the same time, we have continued to pursue our M&A-driven growth strategy. Farmacia Formaggia S.r.l., acquired in July, brings to the Group not only scale and profitability but also distinctive expertise in new business areas. The agreement signed in August to acquire 60% of Farmacia dell'Aquila S.r.l. further reinforces this direction, adding expertise in pharmaceutical procurement, aesthetic medicine, and deblistering.

Our ambition is to progressively evolve Più Medical from a pharmacy consolidation platform into an integrated community healthcare platform, with pharmacies remaining the primary point of access for patients and developing services, expertise, and new growth opportunities around them. We will continue to pursue this strategy with discipline, investing in the integration of the network and selecting acquisition opportunities capable of bringing not only revenue but also profitability, expertise, and industrial value to the Group."

The consolidated results as of June 30, 2026, when compared with the consolidated results for the same period in 2025, should be interpreted in light of the significant corporate transactions that took place in 2025 and the first half of 2026. In particular, for 2025, it should be noted that the Group's operations covered only the last quarter of the year, following the completion of the spin-off transactions from G.S.M. S.r.l. and La Farmaceutica S.p.A. and the acquisitions of the three new pharmacies, which were finalized on October 31, 2025. Meanwhile, the first half of 2026 was marked by the signing of a binding agreement for the acquisition of Farmacia Formaggia S.r.l. ("**Farmacia Formaggia**")(which was subsequently completed on July 2, 2026) and by significant investments made during the period—both for the renovation of the recently acquired pharmacies and for the strengthening of Più Medical's organizational structure, governance systems, and control processes—carried out to support the Company's growth and development in the post-listing context.

In order to illustrate the accounting effects of the aforementioned transactions on a consistent basis, pro forma consolidated financial statements (the "**Pro Forma Consolidated Financial Statements**") have been prepared, solely for illustrative purposes.

These financial statements have been prepared in accordance with valuation criteria consistent with historical data and in compliance with applicable regulations, to reflect the main effects of extraordinary transactions and acquisitions on the balance sheet and consolidated income statement of the group headed by Più Medical (the "**Group**"), as if such transactions had hypothetically occurred on January 1 of each reporting year. In this regard, it should be noted that the pro forma consolidated financial statements as of June 30, 2026, include Farmacia Formaggia's contribution for the entire first half of 2026, as if it had been part of the Group from the beginning of the period.

The pro forma consolidated financial statements are therefore presented to reflect the Group's economic and financial performance, taking into account the extraordinary transactions of the period.

Key pro forma consolidated results as of June 30, 2026

The table below shows the key pro forma consolidated results as of June 30, 2026, compared with the pro forma consolidated results as of June 30, 2025, as reported in the Admission Document relating to the admission to trading of Più Medical ordinary shares on Euronext Growth Milan.

The separate presentation of pro forma data relating to the operations of the pharmacies (the "**Pharmacies**") as compared to those of the Più Medical Corporate Functions[1] is intended to ensure a better understanding and a clearer representation of the Group's financial performance.

[1] "Più Medical Corporate Functions" refers to the centralized functions and related costs supporting the coordination and management of the pharmacy network, including, among others, Finance, Retail Management and Supply Chain Management, as well as costs associated with the Company's listed status.

€/1000	1H 2026 Pharmacies	1H 2026 Più Medical Corporate Functions	1H 2026 PRO FORMA CONSOLIDATED	1H 2025 Pharmacies	1H 2025 Più Medical Corporate Functions	1H 2025 PRO FORMA CONSOLIDATED
Revenue from sales and services	**17.536**	**-**	**17.536**	**13.358**	**-**	**13.358**
EBITDA	**1.876**	**(262)**	**1.614**	**693**	**-**	**693**
EBITDA margin %	*10,7%*		*9,2%*	*5,2%*		*5,2%*
PRO FORMA EBITDA	**2.540**	**(721)**	**1.819**	**1.223**	**(200)**	**1.023**
Pro-forma EBITDA margin %	*14,5%*		*10,4%*	*9,2%*		*7,7%*
Adjusted PRO FORMA EBITDA	**2.540**	**(721)**	**1.819**	**2.183**	**(200)**	**1.983**
Adjusted pro-forma EBITDA margin %	*14,5%*		*10,4%*	*16,3%*		*14,8%*
PRO FORMA RESULTS FOR THE PERIOD	**1.705**	**(1.102)**	**603**	**371**	**(300)**	**71**

Revenues from sales and services are generated primarily by the retail sale of a full range of pharmaceutical products, including private-label lines.

Pro forma consolidated revenues for the period totaled €17.5 million, representing an increase of €4.2 million (+31%) compared to the previous period. The increase is primarily attributable to the revenue generated by the acquisition of Farmacia Formaggia, which contributed €4.0 million in revenue. Farmacia Formaggia also reported adjusted EBITDA of €0.7 million, confirming the quality of the acquisition in terms of profitability as well. The three pharmacies acquired in the fourth quarter of 2025 recorded a revenue increase of €0.1 million (+3.4%) in the first half of 2026 compared to the corresponding period of the previous fiscal year, demonstrating positive growth momentum given their recent inclusion in the Group's scope of operations, which occurred as recently as October 31, 2025. This result takes on further significance in light of the limited integration period and the fact that the effects of the business development initiatives and operational synergies expected from the integration process have not yet fully materialized; the benefits of these are expected to further contribute to volume growth and the enhancement of the acquired assets.

The following is a description of the main pro forma journal entries considered for the purpose of determining the data:

- EBITDA is a measure of the Group's operating performance that reflects the main effects of extraordinary transactions and acquisitions on the income statement as if they had virtually occurred on January 1 of the reporting year;
- Pro forma EBITDA for 2025 also reflects pro forma adjustments related to economic effects, including the recognition of volume discounts and the reversal of shipping charges resulting from new commercial agreements, as well as the inclusion of management fees to reflect a 12-month period of application for the pharmacies acquired in the fourth quarter of 2025, the recognition of Più Medical's overhead costs consistent with the projected operating model, and the exclusion of extraordinary costs related to the IPO process that are not capitalizable under IAS/IFRS. With regard to 2026, the pro forma entries relate to non-recurring costs incurred by Farmacia Formaggia for advisory services aimed at identifying a strategic-industrial partner, for consulting services related to the company's transformation from a partnership to a corporation, and for consulting services

performed in preparation for and prior to the completion of the sale transaction. Since these costs are extraordinary and unrelated to normal business operations, they have been excluded for the purposes of the pro forma presentation;
– Finally, the pro forma adjusted EBITDA for 2025 reflects the adjustment related to the recognition of one-time bonuses granted to management in the amount of €960 thousand, which reflects the adjustment to service costs and, specifically, to extraordinary bonuses approved for directors for the fiscal year ended December 31, 2025.

The **pro forma adjusted EBITDA** for the Pharmacies as of June 30, 2026, stood at €2.5 million, up 16% from €2.2 million as of June 30, 2025 pro forma. This result was achieved despite the significant investments made by Più Medical during the first half of the year to finance the integration, development, and onboarding of new professional staff, particularly to support the acquired pharmacies.

Adjusted pro-forma consolidated EBITDA as of June 30, 2026, stood at €1.8 million, equal to 10.4% of revenue, compared to €2.0 million as of June 30, 2025 (pro-forma), equal to 14.8% of revenue. This change primarily reflects the increase in corporate costs, amounting to €522 thousand, incurred to equip Più Medical with the managerial functions and governance, control, and compliance mechanisms necessary to support a larger platform and continue its growth trajectory. At the operational level, the Group also incurred higher costs for the integration and development of the network of acquired pharmacies, amounting to €351 thousand. These effects were partially offset by the contribution from Farmacia Formaggia, amounting to €708 thousand.

The **pro forma half-year result** was €0.6 million as of June 30, 2026, compared to €0.1 million in the same period of 2025. This change is primarily attributable to the absence of extraordinary expenses incurred in the first half of 2025, related to one-time bonuses paid to management totaling approximately €960,000, as well as the pro forma net income of €492,000 resulting from the acquisition of Farmacia Formaggia. This improvement in earnings was achieved despite the integration and development initiatives carried out during 2026 to strengthen Più Medical's organizational structure, governance systems, and control processes, which are designed to support the Company's growth trajectory in the post-listing context, as already highlighted in the section commenting on *adjusted* pro-forma EBITDA.

Key consolidated results as of June 30, 2026

The table below highlights the key results from the consolidated semiannual report as of June 30, 2026.

€/1000	**1H 2026**
Revenue from sales and services	13.559
EBITDA	1.111
EBITDA margin %	*8,2%*
EBIT	672
EBIT margin %	*5,0%*
Net income for the period	111
of which Group	102
of which third parties	10

Revenue from sales and services as of June 30, 2026, amounted to €13.6 million. This item primarily includes revenue attributable to sales made in Italy, mainly through retail sales, for the first half of 2026, corresponding to the Group's period of operation.

EBITDA totaled €1.1 million as of June 30, 2026, representing 8.2% of revenue.

Personnel expenses totaled €2.4 million, equal to 17.9% of revenue. The number of employees at the end of the period was 88 (of whom 62 were pharmacists and 17 were sales staff).

EBIT amounted to €0.7 million, equal to 5% of revenue, due to depreciation, amortization, and impairment charges totaling €0.4 million.

Net income for the period was €0.1 million.

Key consolidated balance sheet indicators as of June 30, 2026

Group shareholders' equity amounts to €36.7 million, compared to €36.6 million as of December 31, 2025.

The **net financial position** is cash positive by €3.1 million, compared to a cash-positive position of €4.9 million as of December 31, 2025.

The current net financial position was positive at €15.4 million, resulting from cash and cash equivalents of €16.1 million (€18.7 million as of December 31, 2025) and current lease liabilities of €0.7 million.

The decrease in cash and cash equivalents compared to December 31, 2025, primarily reflects the effects of cash outflows related to investments in the renovation of the three pharmacies (Saronnese, F. D'Ambrosio, and Farmacia all'Ippodromo) totaling approximately €1.1 million, the down payment of €1.0 million for the purchase of Farmacia Formaggia, and the balance of approximately €0.5 million paid for the acquisition of the three new pharmacies and the property in Novate Milanese, which were finalized on October 31, 2025, the recognition of interest expense on the ARCANO loan totaling approximately €0.4 million, only partially offset by net cash flow from the pharmacies' operating activities, net of Più Medical Corporate Functions costs.

Non-current net financial debt amounts to €12.3 million, of which €7.4 million relates to medium- to long-term loans and €5.0 million relates to lease liabilities.

The net financial position, excluding the effects of IFRS 16, was cash positive at €8.8 million.

Key events after June 30, 2026

On July 2, 2026, Più Medical completed the acquisition of 100% of the equity of Farmacia Formaggia, a pharmacy located on Corso Buenos Aires in Milan, marking the Company's first acquisition following its IPO in November 2025. For further information on the acquisition of Farmacia Formaggia and the terms and conditions of the transaction, please refer to the press release issued by the Company on July 2, 2026.

On 5 August 2026, Più Medical entered into a binding agreement to acquire 60% of the share capital of Farmacia dell'Aquila S.r.l. ("**Farmacia dell'Aquila"**), the company that owns the historic pharmacy in

Genoa, with the transaction expected to be completed in the fourth quarter of 2026. For further information on the acquisition of Farmacia dell'Aquila and the terms and conditions of the transaction, please refer to the press release issued by the Company on 5 August 2026.

Outlook for business operations

In the second half of 2026, Più Medical will continue to pursue its growth strategy through selective acquisitions by identifying new pharmacies capable of adding value to the Group not only in terms of profitability but also in terms of expertise.

The Company intends to gradually evolve from a pharmacy consolidation platform into an integrated community healthcare platform, which views the pharmacy as the primary point of access for patients and involves the gradual integration of complementary services and expertise.

From an operational and industrial perspective, 2026 will see the Group engaged in implementing multiple commercial and retail initiatives aimed at strengthening the visibility and positioning of the "Più Medical" brand. The planned activities also aim to improve the patient/customer experience through investments in retail locations, the product and service offerings, staff skill development, and the enhancement of IT and digital infrastructure to support the Group's pharmacy network.

***

The consolidated half-yearly financial report as of June 30, 2026, accompanied by the independent auditors' report, will be made available to the public at the Company's headquarters, on the Company's website at https://piumedical.com/ in the *"Investor Relations/Financial Statements and Reports"* section, and on the Borsa Italiana S.p.A. website in the "*Stocks/Documents*" section. The consolidated half-yearly financial report was voluntarily subjected to a limited review in accordance with IAS 34.

This press release is available in the Investor Relations / Press Releases section of the website https://piumedical.com/ and on www.emarketstorage.it.

For the dissemination of regulated information, Più Medical uses the eMarket SDIR network (www.emarketstorage.it), managed by Teleborsa S.r.l., headquartered at Piazza di Priscilla, 4, Rome.

***

CONTACTS

Investor Relator
Fabio Luigi Giordano
Viale Lombardia 62, 21040 Castronno (VA)
+39 0332 896059
investor@piumedical.com

Euronext Growth Advisor & Specialist
Banca Investis S.p.A.
Via Broletto, 5, 20121 Milano
+ 39 0299968127
marco.pelosi@bancainvestis.com

Media Relations
Twister Communications Group

Via Valparaiso, 3 - 20144 Milano
Tel. +39 02438114200
piumedical@twistergroup.it

The Company

Più Medical, founded in 2025 and whose shares are traded on Euronext Growth Milan, currently operates a network of 17 pharmacies and pursues a growth strategy based on the acquisition, integration and development of local pharmacies, alongside the progressive expansion of complementary healthcare services and capabilities. The operating model integrates industrial, managerial, and commercial expertise, leveraging structured processes, economies of scale, and a governance structure capable of supporting future growth.

Pro Forma consolidated financial statements as of June 30, 2026

(prepared in accordance with IAS/IFRS international accounting standards)

CONTO ECONOMICO €/1.000	Farmacie	Struttura Più Medical	CONSOLIDATO PROFORMA H1 2026		Farmacie	Struttura Più Medical	CONSOLIDATO PROFORMA H1 2025	
Ricavi delle vendite e delle prestazioni	17.536	0	17.536	100,0 %	13.358	-	13.358	100,0%
Altri proventi operativi	24	99	122	0,7%	16	-	16	0,1%
Valore della produzione	**17.559**	**99**	**17.659**	**100,7%**	**13.374**	**-**	**13.374**	**100,1%**
Materie prime e materiali di consumo	(11.985)	459	(11.526)	-65,7%	(8.795)	-	(8.795)	-65,8%
Variazione delle rimanenze	235	-	235	1,3%	172	-	172	1,3%
Primo Margine	**5.808**	**559**	**6.367**	**36,3%**	**4.751**	**-**	**4.751**	**35,6%**
Costi per servizi e prestazioni	(1.506)	(418)	(1.924)	-11,0%	(2.222)	-	(2.222)	-16,6%
Costi per godimento di beni di terzi	(107)	(3)	(111)	-0,6%	(18)	-	(18)	-0,1%
Costi del personale	(2.181)	(375)	(2.557)	-14,6%	(1.761)	-	(1.761)	-13,2%
Altri costi operativi	(138)	(24)	(162)	-0,9%	(57)	-	(57)	-0,4%
EBITDA	**1.876**	**(262)**	**1.614**	**9,2%**	**693**	**-**	**693**	**5,2%**
Sconto volumi	*459*	*(459)*	*-*	*0,0%*	407	-	407	*3,0%*
Storno addebito (trasporti)	-	-	-	*0,0%*	157	-	157	*1,2%*
Management fees	-	-	-	*0,0%*	(103)	-	(103)	*-0,8%*
Costi di struttura Più Medical	-	-	-	*0,0%*	-	(200)	(200)	*-1,5%*
Costi per servizi (compensi amministratori)	-	-	-	*0,0%*	69	-	69	*0,5%*
Costi per servizi (costi M&A)	*205*	-	*205*	*1,2%*	-	-	-	*0,0%*
EBITDA PROFORMA	***2.540***	***(721)***	***1.819***	***10,4%***	**1.223**	**(200)**	**1.023**	***7,7%***
Bonus una tantum management	-	-	-	*0,0%*	960	-	960	*7,2%*
EBITDA PROFORMA ADJUSTED	***2.540***	***(721)***	***1.819***	***10,4%***	**2.183**	**(200)**	**1.983**	***14,8%***
Ammortamenti e svalutazioni	(436)	(15)	(451)	-2,6%	(419)	-	(419)	-3,1%
EBIT PROFORMA	***2.104***	***(736)***	***1.368***	***7,8%***	**804**	**(200)**	**604**	***4,5%***
Risultato finanziario	(114)	(318)	(432)	-2,5%	(106)	(226)	(332)	-2,5%
EBT PROFORMA	***1.989***	***(1.054)***	***936***	***5,3%***	**698**	**(426)**	**272**	***2,0%***
Imposte sul reddito	(284)	(48)	(332)	-1,9%	(327)	126	(201)	-1,5%
RISULTATO DEL PERIODO PROFORMA	***1.705***	***(1.102)***	***603***	***3,4%***	**371**	**(300)**	**71**	***0,5%***

STATO PATRIMONIALE €/1.000	CONSOLIDATO PROFORMA H1 2026		CONSOLIDATO PROFORMA 2025		Variazione
Immobilizzazioni immateriali	39.456	91,8%	26.569	80,42%	12.886
Avviamento	39.389	91,6%	26.514	80,25%	12.876
Attività immateriali	66	0,2%	56	0,17%	11
Diritto d'uso	7.068	16,4%	6.145	18,60%	924
Immobilizzazioni materiali	1.889	4,4%	834	2,52%	1.055
Immobilizzazioni finanziarie	7	0,0%	6	0,02%	1
Capitale Immobilizzato	**48.420**	**112,6%**	**33.554**	**101,56%**	**14.867**
Rimanenze	2.782	6,5%	2.131	6,45%	651
Crediti commerciali	1.387	3,2%	824	2,49%	563
Debiti commerciali	(6.642)	-15,5%	(4.589)	-13,89%	(2.053)
Capitale Circolante Commerciale	**(2.473)**	**-5,8%**	**(1.634)**	**-4,95%**	**(839)**
Altre attività correnti	862	2,0%	520	1,57%	342
Altre passività correnti	(5.167)	-12,0%	(1.509)	-4,57%	(3.659)
Crediti (debiti) proforma	148	0,3%	694	2,10%	(546)
Crediti (debiti) tributari netti	1.011	2,4%	1.038	3,14%	(27)
Ratei e risconti netti	909	2,1%	928	2,81%	(19)
Capitale Circolante Netto	**(4.710)**	**-11,0%**	**38**	**0,11%**	**(4.748)**
Fondi per rischi ed oneri	(17)	0,0%	(17)	-0,05%	-
Passività per benefici a dipendenti	(709)	-1,7%	(536)	-1,62%	(173)
CAPITALE INVESTITO NETTO (Impieghi)	**42.983**	**100,0%**	**33.038**	**100,00%**	**9.945**
Debiti finanziari	14.486	33,7%	7.326	22,17%	7.161
Disponibilità liquide e mezzi equivalenti	(16.370)	-38,1%	(18.680)	-56,54%	2.310
Passività a breve termine IFRS 16	818	1,9%	679	2,06%	139
Passività a m/l termine IFRS 16	6.504	15,1%	5.739	17,37%	765
Indebitamento Finanziario Netto	**5.438**	**12,7%**	**(4.936)**	**-14,94%**	**10.375**
Capitale sociale	151	0,4%	151	0,46%	-
Riserva per benefici ai dipendenti	9	0,0%	13	0,04%	(4)
Altre riserve	36.117	84,0%	36.517	110,53%	(400)
Utile (perdita) dell'esercizio	594	1,4%	628	1,90%	(35)
Patrimonio netto di Gruppo	**36.871**	**85,8%**	**37.309**	**112,93%**	**(439)**
Patrimonio netto di terzi	**675**	**1,6%**	**665**	**2,01%**	**10**
TOTALE FONTI	**42.983**	**100,0%**	**33.038**	**100,00%**	**9.945**

Consolidated financial statements as of June 30, 2026

(prepared in accordance with IAS/IFRS international accounting standards)

STATO PATRIMONIALE ATTIVO €/1.000	30/06/2026	31/12/2025
ATTIVITA' NON CORRENTI		
Immobili, impianti e macchinari	1.839	834
Diritto d'uso	5.427	6.145
Avviamento	26.514	26.514
Attività immateriali	66	56
Attività finanziarie non correnti	1.006	6
Altre attività non correnti	909	928
Attività per imposte anticipate	803	775
TOTALE ATTIVITA' NON CORRENTI	**36.564**	**35.257**
ATTIVITA' CORRENTI		
Rimanenze	2.287	2.131
Crediti commerciali	1.034	824
Crediti tributari	406	406
Altre attività e crediti diversi correnti	861	398
Disponibilità liquide e mezzi equivalenti	16.126	18.680
TOTALE ATTIVITA' CORRENTI	**20.715**	**22.438**
TOTALE ATTIVITA'	**57.278**	**57.694**

STATO PATRIMONIALE PASSIVO €/1.000	30/06/2026	31/12/2025
PATRIMONIO NETTO		
Capitale sociale	151	151
Altre riserve	36.393	36.505
Riserva per benefici ai dipendenti	9	13
Utili (perdite) portati a nuovo	68	-
Utile (perdita) dell'esercizio	102	(44)
Totale Patrimonio netto di Gruppo	**36.723**	**36.625**
Capitale e riserve di Terzi	665	661
Riserva per benefici ai dipendenti	0,301	0,207
Utile (perdita) dell'esercizio di pertinenza di terzi	10	3
Totale Patrimonio netto di Terzi	**675**	**665**
TOTALE PATRIMONIO NETTO	**37.397**	**37.290**
PASSIVITA' NON CORRENTI		
Debiti verso banche e altre passività finanziarie non correnti	7.357	7.326
Passività finanziarie per lease non correnti	4.974	5.739
Passività per benefici a dipendenti	584	536
Imposte differite	71	23
Fondi per rischi ed oneri	17	17
TOTALE PASSIVITA' NON CORRENTI	**13.003**	**13.641**
PASSIVITA' CORRENTI		
Debiti verso banche e altre passività finanziarie correnti	-	-
Passività finanziarie per lease correnti	707	679
Debiti commerciali	4.918	4.589
Debiti tributari	71	119
Altre passività e debiti diversi correnti	1.182	1.377
TOTALE PASSIVITA' CORRENTI	**6.878**	**6.764**
TOTALE PASSIVITA'	**19.881**	**20.405**
TOTALE PATRIMONIO NETTO E PASSIVITA'	**57.278**	**57.694**

CONTO ECONOMICO €/1.000	30/06/2026
Ricavi delle vendite e delle prestazioni	13.559
Altri proventi operativi	107
Valore della produzione	**13.666**
Materie prime e materiali di consumo	(8.587)
Variazioni rimanenze	157
Costi per servizi e prestazioni	(1.538)
Costi per godimento beni di terzi	(41)
Costi del personale	(2.428)
Altri costi operativi	(119)
EBITDA	**1.111**
Ammortamenti attività immateriali	(10)
Ammortamenti attività materiali	(86)
Ammortamenti diritto d'uso	(378)
Rettifiche di valore di attività e altri accantonamenti	35
EBIT	**672**
Proventi finanziari	80
Oneri finanziari	(498)
EBT	**254**
Imposte correnti, anticipate, differite	(142)
Risultato dell'esercizio	**111**
di cui Gruppo	102
di cui Terzi	10

RENDICONTO FINANZIARIO €/1.000	30/06/2026
Utile da attività operative al netto di imposte	**111**
Aggiustamenti per riconciliare l'utile al lordo delle imposte con i flussi finanziari netti:	
Ammortamenti e perdita durevole di valore di immobili, impianti e macchinari	86
Ammortamento diritto d'uso	378
Ammortamento e perdita durevole di valore delle immobilizzazioni immateriali	10
(Proventi finanziari)	(80)
Oneri finanziari	408
Costi finanziari su passività finanziarie per leasing	90
Imposte sul reddito	142
Variazione netta TFR e fondi pensionistici	36
(Interessi pagati)	(286)
(Imposte sul reddito pagate)	(227)
Altre operazioni non monetarie	12
Variazioni nel capitale circolante:	0
(Aumento) diminuzione delle rimanenze	(157)
(Aumento) diminuzione dei crediti commerciali	(210)
Aumento (diminuzione) dei debiti commerciali	329
Aumento (diminuzione) dei (crediti) debiti tributari	(49)
Aumento (diminuzione) delle altre (attività) passività non finanziarie	(638)
Flussi finanziari netti da attività operative	**(45)**
Attività d'investimento	
Investimenti netti in immobilizzazioni materiali	(1.090)
Investimenti netti in immobilizzazioni immateriali	(21)
Acquisizione di società controllate, al netto della liquidità acquisita	-
Flussi finanziari netti da attività di investimento	**(1.111)**
Flussi finanziari derivanti dall'attività di finanziamento	
Accensione (rimborsi) di finanziamenti	-
(Aumento) diminuzione dei crediti finanziari	(1.000)
(Pagamenti della quota capitale - passività per leasing IFRS 16)	(397)
Aumento (diminuzione) di capitale	-
Flussi finanziari da attività di finanziamento	**(1.397)**
Variazione netta delle disponibilità liquide	**(2.554)**
Disponibilità liquide a inizio esercizio	**18.680**
Disponibilità liquide a fine periodo	**16.126**

POSIZIONE FINANZIARIA NETTA *€/1.000*	30/06/2026	di cui IFRS 16	31/12/2025	di cui IFRS 16
A. Disponibilità liquide	16.126		18.680	
B. Mezzi equivalenti a disponibilità liquide	-		-	
C. Altre attività finanziarie correnti	-		-	
D. Liquidità (A)+(B)+(C)	**16.126**	**-**	**18.680**	
E. Debiti finanziari correnti	-		-	
F. Parte corrente dell'indebitamento non corrente	707	707	679	679
G. Indebitamento finanziario corrente (E)+(F)	**707**	**707**	**679**	**679**
H. Indebitamento finanziario corrente netto (G)-(D)	**(15.419)**	**707**	**(18.000)**	**679**
I. Debiti finanziari non correnti	12.331	4.974	13.064	5.739
J. Strumenti di debito	-		-	
K. Altri debiti non correnti	-		-	
L. Indebitamento finanziario non corrente (I)+(J)+(K)	**12.331**	**4.974**	**13.064**	**5.739**
M. Indebitamento finanziario netto (H)+(L)	**(3.088)**	**5.681**	**(4.936)**	**6.418**